Replies to post #77325 on Biotech Values

[wallstarb]

ZGEN owes nearlt 300m - its a poor balance sheet. If they get $80m milestones it will look better but still negative net tangibles which isnt a good postion for a development stage bio. Just not my cup of tea. Its hard enough to invest in strong companies over the last year.